PL2040689T3 - Roztwór zawierający N-acetylocysteinę i kwas glukonowy oraz sposoby redukowania, leczenia i zapobiegania stresowi oksydacyjnemu i aktywacji komórek - Google Patents
Roztwór zawierający N-acetylocysteinę i kwas glukonowy oraz sposoby redukowania, leczenia i zapobiegania stresowi oksydacyjnemu i aktywacji komórekInfo
- Publication number
- PL2040689T3 PL2040689T3 PL07764759T PL07764759T PL2040689T3 PL 2040689 T3 PL2040689 T3 PL 2040689T3 PL 07764759 T PL07764759 T PL 07764759T PL 07764759 T PL07764759 T PL 07764759T PL 2040689 T3 PL2040689 T3 PL 2040689T3
- Authority
- PL
- Poland
- Prior art keywords
- solution
- methods
- treat
- reduce
- cell activation
- Prior art date
Links
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 title abstract 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 title abstract 2
- 229960004308 acetylcysteine Drugs 0.000 title abstract 2
- 230000020411 cell activation Effects 0.000 title abstract 2
- 235000012208 gluconic acid Nutrition 0.000 title abstract 2
- 239000000174 gluconic acid Substances 0.000 title abstract 2
- 230000036542 oxidative stress Effects 0.000 title abstract 2
- 239000000243 solution Substances 0.000 abstract 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 1
- 108010024636 Glutathione Proteins 0.000 abstract 1
- 229930003268 Vitamin C Natural products 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 239000000385 dialysis solution Substances 0.000 abstract 1
- 229960003180 glutathione Drugs 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 235000019154 vitamin C Nutrition 0.000 abstract 1
- 239000011718 vitamin C Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80548906P | 2006-06-22 | 2006-06-22 | |
| PCT/EP2007/005466 WO2007147590A2 (en) | 2006-06-22 | 2007-06-21 | Solution and method to reduce, treat and/or prevent oxidative stress and cell activation |
| EP07764759A EP2040689B1 (en) | 2006-06-22 | 2007-06-21 | Solution comprising n-acetylcysteine and gluconic acid, and methods to reduce, treat and/or prevent oxidative stress and cell activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2040689T3 true PL2040689T3 (pl) | 2011-04-29 |
Family
ID=38614318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07764759T PL2040689T3 (pl) | 2006-06-22 | 2007-06-21 | Roztwór zawierający N-acetylocysteinę i kwas glukonowy oraz sposoby redukowania, leczenia i zapobiegania stresowi oksydacyjnemu i aktywacji komórek |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100204328A1 (pl) |
| EP (1) | EP2040689B1 (pl) |
| AT (1) | ATE489950T1 (pl) |
| CA (1) | CA2655644C (pl) |
| DE (1) | DE602007010938D1 (pl) |
| ES (1) | ES2355853T3 (pl) |
| PL (1) | PL2040689T3 (pl) |
| WO (1) | WO2007147590A2 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010112547A1 (en) * | 2009-03-31 | 2010-10-07 | Gambro Lundia Ab | Dialysis precursor composition |
| CN107922922A (zh) | 2015-08-24 | 2018-04-17 | 维特罗利夫瑞典股份公司 | 培养基 |
| RU2709501C1 (ru) * | 2019-10-15 | 2019-12-18 | Виктор Александрович Сисев | Фармацевтическая композиция для парентерального капельного введения |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3583880D1 (de) * | 1984-04-09 | 1991-10-02 | Takeda Chemical Industries Ltd | Stabile interleukin-2-zusammensetzung. |
| JP3714689B2 (ja) * | 1994-10-27 | 2005-11-09 | ユニチカ株式会社 | ビリルビン測定用試薬 |
| US5871769A (en) * | 1996-01-18 | 1999-02-16 | Fleming & Company, Pharmaceuticals | Methods and compositions for the prevention and treatment of diabetes mellitus |
| IT1312086B1 (it) * | 1999-04-21 | 2002-04-04 | Zambon Spa | Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress |
| EP1062879B1 (en) * | 1999-06-26 | 2003-08-27 | B. Braun Melsungen Ag | Aqueous solution for the parenteral nutrition |
| KR100390630B1 (ko) * | 1999-07-02 | 2003-07-07 | 이희발 | 항 산화제를 함유한 복막투석액 |
| ATE311203T1 (de) * | 1999-10-15 | 2005-12-15 | Dow Global Technologies Inc | Dialyselösung die polyglycol als osmotischen mittels enthält |
| US7014990B2 (en) * | 2000-10-13 | 2006-03-21 | Ben O'Mar Arrington | Machine perfusion solution for organ and biological tissue preservation |
| US6955816B2 (en) * | 2001-11-16 | 2005-10-18 | Klysz Beatrice M | Anti-aging skin care composition and uses thereof |
| JP4894219B2 (ja) * | 2004-10-15 | 2012-03-14 | ニプロ株式会社 | ビタミンb群配合末梢静脈栄養輸液 |
| WO2007046757A1 (en) * | 2005-10-17 | 2007-04-26 | Gambro Lundia Ab | Extracorporeal blood cleaning |
-
2007
- 2007-06-21 ES ES07764759T patent/ES2355853T3/es active Active
- 2007-06-21 EP EP07764759A patent/EP2040689B1/en active Active
- 2007-06-21 DE DE602007010938T patent/DE602007010938D1/de active Active
- 2007-06-21 CA CA2655644A patent/CA2655644C/en not_active Expired - Fee Related
- 2007-06-21 US US12/305,481 patent/US20100204328A1/en not_active Abandoned
- 2007-06-21 PL PL07764759T patent/PL2040689T3/pl unknown
- 2007-06-21 AT AT07764759T patent/ATE489950T1/de not_active IP Right Cessation
- 2007-06-21 WO PCT/EP2007/005466 patent/WO2007147590A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE602007010938D1 (de) | 2011-01-13 |
| ES2355853T3 (es) | 2011-03-31 |
| CA2655644C (en) | 2013-01-08 |
| EP2040689B1 (en) | 2010-12-01 |
| CA2655644A1 (en) | 2007-12-27 |
| EP2040689A2 (en) | 2009-04-01 |
| US20100204328A1 (en) | 2010-08-12 |
| WO2007147590A3 (en) | 2008-03-13 |
| WO2007147590A2 (en) | 2007-12-27 |
| ATE489950T1 (de) | 2010-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20091801L (no) | Peristatisk mikropumpe med utskiftbart pumpehode | |
| FI3698630T3 (fi) | Typpioksidin annostelu ja seuraaminen ex vivo -nesteissä | |
| WO2010029401A3 (en) | A procedure and a device for extracorporeal blood treatment using citrate anticoagulation | |
| WO2010098940A3 (en) | One-way replacement valve | |
| BR112014030611A2 (pt) | sistema e método de monitoramento e controle de volume de ultrafiltração durante diálise peritoneal usando bioempedância segmentar | |
| WO2008034068A3 (en) | Intravascular blood pump and catheter | |
| MX2010003871A (es) | Cateter intravenoso con valvula en linea y metodos relacionados a este. | |
| NZ710157A (en) | Use of guanethidine for treating hypertension by local vascular delivery | |
| CY1116197T1 (el) | Διαλυμα εγχυσης και ενεσης της λεβεντοπα | |
| WO2010057262A8 (en) | Heart valve prosthesis and method | |
| WO2007075545A3 (en) | Active drainage system for use in defined natural or surgically created body cavities or lumina | |
| MX349383B (es) | Formulaciones para el tratamiento de diabetes. | |
| WO2009022417A1 (ja) | 腹膜透析液 | |
| PL2040689T3 (pl) | Roztwór zawierający N-acetylocysteinę i kwas glukonowy oraz sposoby redukowania, leczenia i zapobiegania stresowi oksydacyjnemu i aktywacji komórek | |
| DK2175877T3 (da) | Anvendelse af muterede antitrombiner til behandling eller forebyggelse af koagulationssygdomme | |
| WO2008120803A1 (ja) | シリンジポンプを備えた持続的血液浄化装置 | |
| EP2106260A4 (en) | INSULIN SENSITIZERS AND TREATMENT PROCEDURES THEREWITH | |
| TW200740451A (en) | An agent for rising concentration of Adiponectin | |
| MX2009014178A (es) | Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa. | |
| WO2008070353A3 (en) | Tissue plasminogen activator variant uses | |
| GB2473390A (en) | Nutritive compositions and methods of using same | |
| WO2007116428A8 (en) | Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis | |
| RU2007103435A (ru) | Способ патогенетического лечения клещевых нейроинфекций | |
| WO2007112520A3 (fr) | Dispositif de perfusion veineuse implantable | |
| RU2007127114A (ru) | Способ снижения концентрации аммиака в крови с помощью аммоцитов и инкапсулированной глутаминсинтетазы |